VIVUS (VVUS) Tops Q1 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
VIVUS Reports First Quarter 2015 Financial Results
May 5, 2015 4:01 PM EDTMOUNTAIN VIEW, CA -- (Marketwired) -- 05/05/15 -- VIVUS, Inc. (NASDAQ: VVUS)Â (the "Company"), a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health, today provided a business update and reported its financial results for the first quarter ended March 31, 2015.
"We have sharpened the focus of our Qsymia® commercial campaign, with new emphasis for the sales force on the most productive healthcare providers," said Seth H. Z. Fischer, CEO. "Pilot programs are underway that will offer targeted prescribers... More



